Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says

This article was originally published in The Pink Sheet Daily

Executive Summary

National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.

You may also be interested in...



NICE To Release Final Alzheimer's Guidance Nov. 22

Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.

NICE To Release Final Alzheimer's Guidance Nov. 22

Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.

NICE To Hear Appeals On Alzheimer’s Appraisal

The U.K. National Institute for Health & Clinical Excellence will hear five appeals against a final appraisal determination that limits recommended National Health Service coverage of four Alzheimer's disease treatments

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel